Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > SwissMedic – Enhanced Pharmacovigilance FAQ

Enhanced Pharmacovigilance FAQ

Philippe Calandra 22 January 2021 All news
  • ← Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 January 2021
  • FDA Adverse Event Reporting System (FAERS) Electronic Submissions →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • European regulation on clinical trials for medicinal products: The end of the transition period
  • The ANSM publishes its haemovigilance report for 2023
  • User’s booklet – ANSM
Copyright © 2018 - Pharmya - Legal terms - Quality Policy